Efficacy and safety of ramucircumab in treatment of advanced non-small cell lung cancer：a Meta analysis
10.3872/j.issn.1007-385x.2018.05.013
- VernacularTitle:雷莫芦单抗治疗晚期非小细胞肺癌有效性及安全性的Meta分析
- Author:
MA Xiaoli
1
;
CAO Leiyu
1
;
WANG Xiao
1
;
LIU Juan
1
;
ZHANG Qian
1
;
ZHANG Li
1
Author Information
1. Department of Internal Medicine VIP, The FirstAffiliated Hospital of Xinjiang Medical University, Urumqi 830054, Xinjiang, China
- Publication Type:Journal Article
- Keywords:
ramcircumab;
non small cell lung cancer;
effectiveness;
safety;
Meta analysis
- From:
Chinese Journal of Cancer Biotherapy
2018;25(5):515-521
- CountryChina
- Language:Chinese
-
Abstract:
[Abstract] Objective: To systematically evaluate the efficacy and safety of ramcircumab in the treatment of advanced non-small cell lung cancer (NSCLC) by a Meta-analysis. Methods: The randomized controlled clinical trials of ramcircumab in the treatment of advanced non-small cell lung cancer were retrieved from Cochrane Library (2017, Issue 8), Web of Science, Pubmed, EMbase, Wanfang Database, CNKI, CBM, Chinese Science and TechnologyAcademic Journal andASCO, ESMO main conference database, with the enddate of September 1, 2017. Two independent reviewers selected the literatures, extracted the data, and assessed the quality of the included studies. The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse reactions in NSCLC patients of ramcircumab group and control group were analyzed by RevMan5.3 software. Results: Three RCTs were finally included in this meta-analysis. A total of 1 545 NSCLC patients were enrolled, including 777 in ramcircumab group and 768 in control group. The PFS and OS of NSCLC patients in the ramcircumab group were all better than those of the control group (HR=0.77,95%CI[0.69-0.85], P<0.01; HR=0.88, 95%CI[0.78-0.99], P<0.05). However, there was no statistically significant difference in the ORR between the ramcircumab group and the control group (RR=1.33, 95%CI[0.68-2.61], P>0.05). Compared with docetaxel single-agent second-line treatment, Ramcircumab combined with docetaxel can prolong PFS and OS of advanced NSCLC patients (HR=0.77, 95%CI[0.69-0.86], P< 0.01; HR=0.86, 95%CI [0.76-0.98], P<0.05). The most serious adverse reaction in the ramcircumab group was hypertension (RR=3.33, 95%CI[1.83-6.05], P<0.01); whereas the incidences of nausea, vomiting, diarrhea, loss of appetite, fatigue, proteinuria, neutropenia, leukopenia, thrombocytopenia, and bleeding etc. showed no significant differences between the two groups (all P>0.05). Conclusion: Ramcircumab can prolong PFS and OS of patients with advanced NSCLC. The main adverse reaction is hypertension.
- Full text:20180513.pdf
